Bupropion Carlat Reports | Carlat Publishing

Clinical Update

Treatment of Antipsychotic-Induced Weight Gain

From The Carlat Psychiatry Report, College Mental Health

Topics: Antipsychotics | Bupropion | Dosing | Lithium | Schizophrenia

Antipsychotic-induced weight gain can decrease medication adherence, with a domino effect of negative consequences on the psychiatric illness. Recently the FDA approved the first therapy to address this problem: Lybalvi, a combination of olanzapine and samidorphan. In this article, I’ll look at how it compares with other treatments for antipsychotic-i

Clinical Update

Six Tips From Prescribing Psychotropics

From The Carlat Psychiatry Report, ADHD

Every day we are faced with prescribing dilemmas that don’t have ready answers. Instant or extended release? Brand or generic? With food or without? How should we adjust dosing to account for drug interactions, age, gender, ethnicity, or genetic testing results? Our new textbook Prescribing Psychotropics: From Drug Interactions to Pharmacogenetics is

Clinical Update

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

From The Carlat Hospital Psychiatry Report, Metabolic Side Effects

Topics: | | | | | | | | | | | | | | | | | | | | Aripiprazole Benzphetamine Bupropion Diabetes Diethylpropion Exercise Insulin resistance Liraglutide Metabolic syndrome Metformin Naltrexone olanzapine Phendimetrazine Phentermine Samidorphan Semaglutide Side Effects Topiramate Waist circumference Weight gain Ziprasidone

Many psychiatric medications cause weight gain, including mood stabilizers, antidepressants, and especially antipsychotics. Most weight gain secondary to antipsychotic use occurs in the first 6 months of therapy, so it’s important to monitor weight closely and intervene early in a patient’s treatment. We counsel patients at every visit about healthy

Research Update

Varenicline and Bupropion: Soaring Again With EAGLES?

From The Carlat Addiction Treatment Report, Medical Issues in Addiction Practice

Review of: Anthenelli RM et al, Lancet 2016;387(10037):2507–2520 Varenicline (Chantix) and bupropion (Zyban and others) are effective treatments for tobacco use disorder, but their use (and sales) took a big hit in 2009 when the FDA slapped both with black box warnings linking them to psychiatric complications, including suicidal ideation. Although

Expert Q&A

The Psychopharmacology Algorithm Project

From The Carlat Psychiatry Report, Psychopharmacology Algorithms

TCPR: What would be the biggest change in practice if psychiatrists followed your algorithms?Dr. Osser: One area is bipolar depression. This is a disorder where there is an exceptionally large deviation between what the evidence says and what people are doing, especially when it comes to antidepressants. They are still being used rampantly, even in pati

Research Update

Optimal Antidepressant Doses in Major Depression

From The Carlat Psychiatry Report, Bipolar II

Review of: Furukawa TA et al, Lancet Psychiatry;2019;6(7):601–609 Type of study: Systematic review and meta-analysis Most antidepressants do not have a linear response curve. In other words, the benefits level off as the dose goes up. If the dose gets too high, the side effects start to outweigh those diminishing returns. What’s not clear is whe

Expert Q&A

Inflammatory Biomarkers in Depression

From The Carlat Psychiatry Report, Inflammation and Depression

TCPR: What is inflammation? Dr. Miller: Inflammation is the body’s natural response to infection or wounding. It’s important for survival, but if it goes on too long it damages the body in various ways. It contributes to heart disease, cancer, metabolic disorders, and neurodegenerative disorders. Ultimately, it can change set points in the brain th

Highlights

Highlights From This Issue

From The Carlat Psychiatry Report, Inflammation and Depression

Inflammation contributes to treatment resistance in depression and can be measured with a blood test, C-reactive protein (CRP). An elevated CRP predicts a favorable response to certain antidepressants, as well as specific lifestyle interventions. Nuedexta’s expanded use in dementia is based on questionable efficacy, but it is safer than many

Clinical Update

Treating Sexual Dysfunction in Women

From The Carlat Psychiatry Report, Mental Health Apps

With the marketing of two new treatments for female sexual dysfunction, one thing is certain: You can expect to see more patients asking for these medications. What’s less certain is whether they will work. Flibanserin (Addyi) and bremelanotide (Vyleesi), the two FDA-approved treatments, both have small effect sizes (0.3–0.4) on various measures o

Research Update

Does Augmenting Varenicline with Bupropion Work Better than Varenicline Alone?

From The Carlat Addiction Treatment Report, Traumatic Brain Injury and Addiction

Topics: Bupropion | Research Update | Smoking Cessation | Varenicline

Review Of: Cinciripini PM et al, Addiction 2018;113:1673-1682 We have a good array of smoking cessation treatments to choose from, including nicotine replacement therapy (NRT), bupropion, and varenicline. Varenicline is the most effective monotherapy agent, somewhat better than bupropion and single-product NRT, and comparable to combination NRT. Theo